Shares of Mesa Laboratories (MLAB) surged 5.2% in pre-market trading on Tuesday, following the company's impressive third-quarter fiscal 2025 results and upbeat outlook.
The life science tools and quality control solutions provider reported better-than-expected earnings of $2.72 per share, surpassing analysts' estimates by a wide margin. Revenue also came in higher at $62.84 million, beating expectations by nearly 7%.
The strong performance was driven by solid growth across all business segments, particularly in the Biopharmaceutical Development and Calibration Solutions divisions. The company's strategic acquisitions, including GKE, also contributed to the revenue growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.